Format

Send to

Choose Destination
Ann Thorac Surg. 1999 Apr;67(4):927-32.

Prognostic factors in clinical stage I non-small cell lung cancer.

Author information

1
Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. kjsuzuki@east.ncc.go.jp

Abstract

BACKGROUND:

Management of patients with early-stage lung cancer but a poor prognosis is controversial.

METHODS:

Between January 1987 and December 1994, 365 patients with clinical stage I disease underwent surgical resection at our hospital. Eight preoperative clinical variables were entered into univariate and multivariate analyses to determine their impacts on 5-year survival.

RESULTS:

The 3-year and 5-year survival rates were 78.1% and 66.5%, respectively. In the multivariate analysis, clinical T2 status and preoperative high serum carcinoembryonic antigen levels were independent significant factors indicative of a poor prognosis (hazard ratio, 2.20 and 1.88, respectively). Patients with both of these factors had 3-year and 5-year survival rates of 65% and 38% (p<0.001), and the risk of death for this subgroup was 4.14 times greater than that of the overall clinical stage I population.

CONCLUSIONS:

A subgroup with clinical T2 disease and preoperative high serum carcinoembryonic antigen levels had a significantly poorer prognosis among patients with clinical stage I lung cancer. For this subgroup, a complete preoperative staging workup and multimodal therapy, especially induction chemotherapy, instead of surgical intervention alone could be beneficial.

PMID:
10320230
DOI:
10.1016/s0003-4975(99)00140-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center